PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290356
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290356
Global Lower Respiratory Tract Therapeutics Market - 2023-2030
Market Overview
The Global Lower Respiratory Tract Therapeutics Market size reached US$ 32,312.9 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 56,251.7 million by 2030. The global lower respiratory tract therapeutics market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030). The key market trend is the widespread increase in industry smoke-related and smoking respiratory diseases.
For instance, in April 2023, Missouri's campaign launched "Tobacco is Changing", to educate parents about the different candy-flavored tobacco products tempting children into addiction. It is also the reality of the tobacco landscape - especially when it comes to e-cigarettes.
Lower respiratory tract therapeutics focuses on the diagnosis, treatment, and management of diseases and disorders of lower respiratory tract infections These infections are an important cause of indirect obstetric death. Pregnant patients are at increased risk of complications such as respiratory failure and empyema. Lower respiratory tract therapeutics are designed to address a range of respiratory conditions such as asthma, COPD, respiratory infections, cystic fibrosis and so on.
The lower respiratory tract therapeutics market is driven by factors such as the increasing prevalence of lower respiratory tract diseases, the rising aging population, increasing awareness and diagnosis, government initiatives and healthcare policies, environmental factors (such as air pollution, climate change, and allergens), and technological advancements.
For instance, in April 2023, The World Health Organization (WHO) released Universal access to rapid tuberculosis diagnostics, setting benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs) to increase bacteriologically-confirmed TB and detection of drug resistance and reduce the time to diagnosis. WHO-recommended rapid diagnostics are highly accurate, cost-effective, reduce the time to treatment initiation, and impact patient-important outcomes.
Market Dynamics
Increasing Prevalence Of Lower Respiratory Tract Diseases
The increasing prevalence of lower respiratory tract diseases is the major factor driving the market share during the forecast period. Lower respiratory tract diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and bronchitis, impose a significant burden on global healthcare systems. The growing prevalence of these diseases means a larger patient population in need of effective therapeutics, leading to increased market demand.
For instance, in May 2023, Grifols, a global leader in plasma-derived medicines and innovative diagnostic solutions, announced that it launched its AlphaID at-home genetic health risk service (AlphaID At Home), the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of COPD.
Higher Risk Of Adverse Effects
Adverse effects associated with lower respiratory tract therapeutics, such as medications used for asthma or COPD, can raise safety concerns among patients and healthcare professionals. The risk of adverse effects may discourage patients from initiating or continuing treatment, leading to suboptimal disease management and reduced market demand.
Continuous monitoring of the safety profile of lower respiratory tract therapeutics is crucial to identify and manage adverse effects effectively. Pharmacovigilance efforts help ensure early detection and appropriate management of adverse effects, maintaining patient confidence and market demand.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a profound impact on the healthcare industry, including the lower respiratory tract therapeutics market. While the pandemic has highlighted the importance of respiratory health, it has also diverted resources and attention away from other respiratory conditions. Additionally, disruptions in supply chains, clinical trials, and healthcare services have posed challenges for the market.
The pandemic has disrupted ongoing clinical trials for lower respiratory tract therapeutics. Many trials were paused, delayed, or modified to prioritize COVID-19 research and ensure patient safety. This interruption in clinical trial activities may delay the development and regulatory approval of new therapies, affecting the future pipeline of lower respiratory tract therapeutics.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict has had a significant impact on the lower respiratory tract therapeutics market. The war may disrupt research and development activities, including the development of new therapies or clinical trials. Limited resources, infrastructure damage, and the displacement of researchers can hinder progress in respiratory therapeutics research.
The conflict can contribute to public health challenges, including the increased risk of respiratory infections due to overcrowding, poor sanitation, and displacement. These factors can lead to a higher burden of respiratory diseases and may require increased access to lower respiratory tract therapeutics.
Segment Analysis
The global lower respiratory tract therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.
Based on Disease Type, The Asthma Therapeutics Segment Is Expected To Dominate The Market Share
The market for asthma therapeutics held 45.3% of the global lower respiratory tract therapeutics market share in 2022. Asthma is a prevalent chronic respiratory condition affecting millions of people worldwide. The high prevalence of asthma contributes to a larger patient population requiring ongoing management and treatment, which drives the demand for asthma therapeutics.
Asthma management involves a range of therapeutics to control and prevent symptoms. These include bronchodilators (both short-acting and long-acting), inhaled corticosteroids, combination inhalers, leukotriene modifiers, and monoclonal antibodies targeting specific inflammatory pathways. The availability of multiple treatment options within the asthma therapeutics segment provides choices for healthcare professionals to tailor treatment plans to individual patient needs.
For instance, in May 2023, Alkem Laboratories, a leading pharmaceutical company, announced the launch of its initiative 'Reliever Free India' to raise awareness about Asthma among physicians and Asthma patients. This initiative aims to spread awareness of the hazards of over-usage of reliever medications and substitute it with SMART therapy i.e., needing only one inhaler for both 'daily' and 'reliever' asthma treatment.
Geographical Analysis
North America Holds The Largest Market Share Due To The High Disease Burden And Technological Advancements
North America held 38.1% market share for the lower respiratory tract therapeutics market in 2022 due to the high disease burden and technological advancements in treatment options. North America has a significant burden of lower respiratory tract diseases, including asthma, COPD, and respiratory infections. The region's population, lifestyle factors, environmental exposures, and healthcare infrastructure contribute to the prevalence of these conditions.
North America has witnessed significant technological advancements in the field of respiratory medicine. This includes the development of advanced inhalation devices, targeted biologics, digital health solutions, and precision medicine approaches for lower respiratory tract diseases. These technological advancements enhance treatment efficacy, patient convenience, and disease management, further strengthening the market share of North America.
Competitive Landscape
The major global players in the market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi S.A, Pfizer Inc., GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc.
Why Purchase the Report?
- To visualize the global lower respiratory tract therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of lower respiratory tract therapeutics market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global lower respiratory tract therapeutics market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Disease Type
- 3.2. Snippet by Drug Class
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by End-User
- 3.6. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing prevalence of lower respiratory tract diseases
- 4.1.1.2. Harmful environmental factors
- 4.1.2. Restraints
- 4.1.2.1. Higher risk of adverse effects
- 4.1.2.2. Limited treatment options
- 4.1.3. Opportunity
- 4.1.3.1. Technological advancements in treatment procedures
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer's Strategic Initiatives
- 6.6. Conclusion
7. By Disease Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 7.1.2. Market Attractiveness Index, By Disease Type
- 7.2. Asthma*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. COPD
- 7.4. Pneumonia
- 7.5. Tuberculosis
- 7.6. Bronchitis
- 7.7. Others
8. By Drug Class
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 8.1.2. Market Attractiveness Index, By Drug Class
- 8.2. Antibiotics*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Non-Steroidal Anti-Inflammatory Drugs
- 8.4. Cough Suppressants
- 8.5. Nasal Decongestants
- 8.6. Others
9. By Route of Administration
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.1.2. Market Attractiveness Index, By Route of Administration
- 9.2. Oral*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Parenteral
- 9.4. Others
10. By Distribution Channel
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Hospital Pharmacies*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Retail Pharmacies
- 10.4. Online Pharmacies
11. By End-User
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.1.2. Market Attractiveness Index, By End-User
- 11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Specialty Clinics
- 11.4. Homecare
- 11.5. Others
12. By Region
- 12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
- 12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.2.8.1. The U.S.
- 12.2.8.2. Canada
- 12.2.8.3. Mexico
- 12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.3.8.1. Germany
- 12.3.8.2. The UK
- 12.3.8.3. France
- 12.3.8.4. Italy
- 12.3.8.5. Spain
- 12.3.8.6. Rest of Europe
- 12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.4.8.1. Brazil
- 12.4.8.2. Argentina
- 12.4.8.3. Rest of South America
- 12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.5.8.1. China
- 12.5.8.2. India
- 12.5.8.3. Japan
- 12.5.8.4. Australia
- 12.5.8.5. Rest of Asia-Pacific
- 12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13. Competitive Landscape
- 13.1. Competitive Scenario
- 13.2. Market Positioning/Share Analysis
- 13.3. Mergers and Acquisitions Analysis
14. Company Profiles
- 14.1. F. Hoffmann-La Roche Ltd.
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
- 14.2. Teva Pharmaceutical Industries Ltd.
- 14.3. Sanofi S.A
- 14.4. Pfizer Inc.
- 14.5. GSK plc
- 14.6. Novartis AG
- 14.7. AstraZeneca
- 14.8. Johnson & Johnson Private Limited
- 14.9. Sun Pharmaceutical Industries Ltd.
- 14.10. Merck & Co., Inc
LIST NOT EXHAUSTIVE
15. Appendix
- 15.1. About Us and Services
- 15.2. Contact Us
